中化新网讯 近日，湖北省经信厅下发《关于认定工业母机智能数控系统等省级制造业创新中心的通 知》，将4个制造业创新中心认定为省级制造业创新中心。 上述4个创新中心为：武汉市华中数控股份有限公司牵头培育的"湖北省工业母机智能数控系统创新中 心"、武汉市嘉必优生物技术（武汉）股份有限公司牵头培育的"湖北省营养素合成生物制造业创新中 心"、咸宁市真奥金银花药业有限公司牵头培育的"湖北省抗病毒中药制剂制造业创新中心"、随州市毅 兴智能装备股份有限公司牵头培育的"湖北省精密数控机床装备制造业创新中心"等。 湖北省经信厅表示，希望上述认定省级制造业创新中心进一步整合行业创新资源，坚持相关产业关键共 性技术研发，加强创新成果工程化能力建设，加快技术扩散和产业化应用，服务产业创新和高质量发 展。创新中心所在地经信部门要进一步加大对创新中心的支持力度，指导和支持其提升创新能力，提升 相关产业基础高级化和产业链现代化水平，为推动湖北制造业高质量发展做出新的贡献。 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structure and transforming economic models [1]. Group 1: Current Status and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current state and trends of biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this sector [7]. Group 2: Policy Landscape - The white paper outlines major domestic and international policies affecting biomanufacturing from 2024 to 2025, providing insights into regulatory frameworks [7]. Group 3: Industry Map and Applications - It presents a comprehensive map of the Chinese biomanufacturing industry and identifies key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [7]. Group 4: Key Enterprises - The report selects ten leading enterprises in the Chinese biomanufacturing sector and details the strategic directions of 15 listed companies in synthetic biology [7][8]. Group 5: Investment and Challenges - The document discusses the investment landscape in synthetic biology from 2024 to mid-2025 and addresses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [7].

(文/解红娟 编辑/张广凯) "该辟谣的都辟谣了。" 在业内人士看来，尽管目前尚未有官方明确通知，但瑞士联邦食品安全局（BLV）的相关结论，已然变 相坐实了此次涉事ARA（花生四烯酸）原料的供应商正是嘉必优。 近日，瑞士《每日广讯报》（Tages-Anzeiger）报道，瑞士联邦食品安全局（BLV）表示，受污染的微 量原料花生四烯酸（ARA）来自中国供应商，该公司是全球三大ARA生产商之一。 此消息一出，作为国内ARA行业龙头企业的嘉必优，瞬间被推至舆论风口浪尖。 观察者网了解到，全球ARA市场的三大核心生产商分别为荷兰帝斯曼-芬美意、中国嘉必优以及中国润 科生物。在污染事件爆发后，帝斯曼-芬美意、中国润科生物均迅速发声撇清关联，唯有嘉必优始终没 有正面回应。 具体来看，帝斯曼-芬美意明确表示"涉事问题ARA原料并非由其供应"，并称作为全球ARA营养原料的 长期可靠供应商，始终将产品质量与安全置于首位，其生产的life's ARA完全按照全球最高婴配级标准 生产，确保每一步都可控、可溯、可靠。 同时，帝斯曼-芬美意还透露，受此次事件影响，其ARA原料需求激增，公司将全力协调产能以满足市 场需求。 润科生物则发 ...

| | | 1月26日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 热点 | 德龙汇能 | 不涉及芯片及相关业务 | | | 东方日升 | 光伏产品未直接向商业航天卫星公司供货 | | 项目投资 | 川环科技 | 拟约11亿元投建川环科技(华东)智造总部基地 | | 合同中标 | 山科智能 | 中标智慧水务平台开发项目 | | 业绩换告 | 均胜电子 | 预计2025年归母净利润约13.5亿元,同比增长40.56% | | 股权转让 | 紫金矿业 | 拟收购AlliedGold Corporation 100%股权 | | 回购 | 吉祥航空 | 已实际回购1.67%公司股份 | | 增减持 | 开普检测 | 董事长姚致清拟减持不超过3%股份 | | 其他 | 浙海德曼 | 拟定增募资不超15.17亿元 | | | 特宝生物 | 拟发行可转债募资不超15.33亿元 片脂磨汇 | 【热点】 浙文互联(600986.SH)：旗下"派智"数字人业务产生的收入和利润占公司营业收入和净利润的比例均不到 1%，占比较小 东方日升(300118.SZ)：光伏产品未直接向 ...

格隆汇1月26日丨嘉必优(688089.SH)公布，截至本公告披露日，公司已完成本次股份回购。公司通过上 海证券交易所交易系统以集中竞价交易方式累计回购公司股份116万股，占公司总股本的0.6892%，回 购最高价格28.58元/股，回购最低价格20.84元/股，回购均价25.86元/股，使用资金总额2999.86万元。 ...

每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 王晓波） 每经AI快讯，嘉必优1月26日晚间发布公告称，截至本公告披露日，公司已完成本次股份回购。公司通 过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份约116万股，占公司总股本的 0.6892%，回购最高价格28.58元/股，回购最低价格20.84元/股，回购均价25.86元/股，使用资金总额约 3000万元。 ...

证券代码：688089 证券简称：嘉必优 公告编号：2026-002 嘉必优生物技术（武汉）股份有限公司 关于第二期股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 三、回购期间相关主体买卖股票情况 | 回购方案首次披露日 | 2025/1/25 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 1 1 | 25 | 日~2026 | 年 | 日 25 | | 预计回购金额 | 1,500万元~3,000万元 | | | | | | 回购价格上限 | 35元/股 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 1,159,989股 | | | | | | 实际回购股数占总股本比例 | 0.6892% | | | | | | 实际回购金 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：环球网 【环球网消费综合报道】继雀巢之后，法国乳制品企业拉克塔利斯也启动了大规模奶粉召回，这两起相 继发生的国际食品安全事件迅速波及国内产业链，将国内最大的ARA（花生四烯酸）供应商嘉必优 （688089.SH）推向了风口浪尖。 据央视新闻报道，1月21日，法国乳企拉克塔利斯公司宣布，在18个国家和地区召回多个批次的婴幼儿 奶粉，原因是相关产品可能含有蜡样芽孢杆菌毒素，存在引发腹泻和呕吐等风险。此前在1月初，雀巢 也因供应商提供的一款ARA油脂原料存在质量问题，在欧洲多国对一批婴儿配方奶粉实施了预防性召 回。英国食品标准局指出，蜡样芽孢杆菌具有高度热稳定性，可能在冲调过程中存活，引发食源性疾 病。 针对雀巢的召回事件，国务院食安办、市场监管总局高度重视，已督促雀巢（中国）有限公司落实主体 责任，召回在中国境内销售的相关批次产品。在这一背景下，作为雀巢等国内外知名婴幼儿配方奶粉企 业的ARA供应商，嘉必优受到市场广泛关注。1月13日，嘉必优收到上交所监管工作函，督促其依法履 行信息披露义务，市场普遍认为这与雀巢奶粉召回事件高度相关。 图片来源 于海关总署进 ...

Core Insights - The nutritional functional food industry is experiencing significant growth driven by national policies, increased health awareness, and rising living standards. The market is projected to reach 288 billion yuan by 2025 and 328 billion yuan by 2026 [1][5]. Industry Overview - Nutritional functional foods are defined as foods that contain ingredients beneficial to human health, excluding health foods that require special approval. This category includes special dietary foods and regular packaged foods [2][3]. - The industry is characterized by a diverse range of products and applications, with health snacks being the largest segment, followed by gut health, beauty nutrition, weight management, and sports nutrition [1][5]. Market Size and Growth - The market size for nutritional functional foods in China is expected to grow from 144 billion yuan in 2019 to 288 billion yuan in 2025, with a further increase to 328 billion yuan by 2026 [5][6]. - Specific market segments for 2025 include health snacks at 103 billion yuan (35.76%), gut health at 65 billion yuan (22.57%), beauty nutrition at 39 billion yuan (13.54%), weight management at 36 billion yuan (12.50%), and sports nutrition at 22 billion yuan (7.64%) [1][5]. Industry Structure - The industry operates on a contract manufacturing model, where one party (the client) outsources production to another party (the contractor). This model allows for specialization in production while the client focuses on marketing and brand management [3][4]. - The supply chain includes upstream raw materials such as vitamins, proteins, and minerals, while the midstream involves research, production, and marketing [6]. Competitive Landscape - The competitive landscape is fragmented, with a few leading companies dominating the market. The top five companies accounted for 17.3% of the market share in 2023, up from 13.9% in 2022 [8]. - Major players in the industry include Hengmei Health, Xianle Health, Dajiang Biotechnology, and others, each with unique advantages [7][8]. Regulatory Environment - Recent government policies, such as the "National Food and Nutrition Development Outline (2025-2030)," aim to promote the nutritional functional food industry by emphasizing innovation and quality in food production [7]. Future Trends - The demand for health-oriented products is expected to grow due to rising income levels and an aging population, creating a favorable environment for the nutritional functional food industry [8].

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can help optimize industrial structures and transform economic models [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current status and trends in biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this field [5]. Group 2: Policy Landscape - The white paper discusses major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. Group 3: Industry Map and Applications - It provides a comprehensive map of the Chinese biomanufacturing industry and analyzes the industry chain along with key application directions, including biomanufacturing in pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The report identifies ten leading enterprises in the Chinese biomanufacturing sector, detailing their contributions and roles within the industry [5][6]. Group 5: Company Strategies - It outlines the synthetic biology strategies of 15 listed companies, summarizing their development approaches and corresponding popular products [5][6]. Group 6: Investment and Challenges - The white paper reviews the investment and financing situation in domestic synthetic biology from 2024 to mid-2025 and discusses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [5][6].